$RLFTF DD by HANS on Yh-0: RLF-100 (Aviptadil),
Post# of 653
(Total Views: 323)
Posted On: 04/28/2021 7:49:26 AM
$RLFTF DD by HANS on Yh-0: RLF-100 (Aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP) has been granted Fast Track Designation by the US FDA for the treatment of Critical COVID-19 with Respiratory Failure.
We describe the clinical course of the first patient treated with this investigational medication in an open label manner -- a 54 year old patient suffering antibody-mediated rejection of his double lung transplant who contracted COVID-19 with respiratory failure refractory to all currently available therapies.
He received three infusions of RLF-100 under an FDA-approved emergency use IND. Within 24 hours of the third infusion, substantial improvement in oxygen saturation and radiographic improvement in characteristic COVID-19 pneumonitis was noted.
He was discharged from intensive care at that point and returned home at 1 week on room air.
Replies
Mt:
And no EUA / NDA. This world is crazy.
HANS
Our talented team of scientists, determined to do their part to contribute to the fight against the worst healthcare disaster in 100 years, had a brilliant idea to repurpose a legacy compound, RLF-100TM (aviptadil), a recombinant form of a naturally occurring peptide found in the lung - Vasoactive Intestinal Peptide (VIP) - to protect the lung from injury due to COVID-19.
Taking advantage of the extraordinary measures implemented in the U.S. to speed up clinical research for COVID-19 therapeutics, Relief partnered with NeuroRx Inc., a U.S. based biotech that excels at innovative novel therapeutic development for rapid deployment.
Ten weeks from concept to clinic, we began our journey to providing this potentially life-saving drug to critical COVID-19 patients.
We describe the clinical course of the first patient treated with this investigational medication in an open label manner -- a 54 year old patient suffering antibody-mediated rejection of his double lung transplant who contracted COVID-19 with respiratory failure refractory to all currently available therapies.
He received three infusions of RLF-100 under an FDA-approved emergency use IND. Within 24 hours of the third infusion, substantial improvement in oxygen saturation and radiographic improvement in characteristic COVID-19 pneumonitis was noted.
He was discharged from intensive care at that point and returned home at 1 week on room air.
Replies
Mt:
And no EUA / NDA. This world is crazy.
HANS
Our talented team of scientists, determined to do their part to contribute to the fight against the worst healthcare disaster in 100 years, had a brilliant idea to repurpose a legacy compound, RLF-100TM (aviptadil), a recombinant form of a naturally occurring peptide found in the lung - Vasoactive Intestinal Peptide (VIP) - to protect the lung from injury due to COVID-19.
Taking advantage of the extraordinary measures implemented in the U.S. to speed up clinical research for COVID-19 therapeutics, Relief partnered with NeuroRx Inc., a U.S. based biotech that excels at innovative novel therapeutic development for rapid deployment.
Ten weeks from concept to clinic, we began our journey to providing this potentially life-saving drug to critical COVID-19 patients.
(0)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
Scroll down for more posts ▼